Affordable Access

Access to the full text

Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers

Authors
  • Takeuchi, Satoshi1, 2
  • Rohren, Eric M.2, 3
  • Abdel-Wahab, Reham4, 5
  • Xiao, Lianchun6
  • Morris, Jeffrey S.6
  • Macapinlac, Homer A.2
  • Hassan, Manal M.3
  • Kaseb, Ahmed O.4, 7
  • 1 Hokkaido University Graduate School of Medicine, Department of Medical Oncology, North 15 West 7 Kita-ku, Sapporo, Japan , Sapporo (Japan)
  • 2 The University of Texas MD Anderson Cancer Center, Department of Nuclear Medicine, 1515 Holcombe Blvd., Unit 1483, Houston, TX, 77030, USA , Houston (United States)
  • 3 Baylor College of Medicine, Department of Radiology, One Baylor Plaza, Houston, TX, 77030, USA , Houston (United States)
  • 4 The University of Texas MD Anderson Cancer Center, Department of Gastrointestinal Medical Oncology, 1515 Holcombe Blvd., Unit 426, Houston, TX, 77030, USA , Houston (United States)
  • 5 Assiut University Hospital, Clinical Oncology Department, Al Hamraa Ath Thaneyah, Qesm Than Asyut, Assiut, Egypt , Assiut (Egypt)
  • 6 The University of Texas MD Anderson Cancer Center, Department of Biostatistics, 1515 Holcombe Blvd., Unit 1411, Houston, TX, 77030, USA , Houston (United States)
  • 7 The University of Texas MD Anderson Cancer Center, Department of Gastrointestinal Medical Oncology, 1515 Holcombe Blvd., Unit 1483, Houston, TX, 77030, USA , Houston (United States)
Type
Published Article
Journal
European Journal of Nuclear Medicine
Publisher
Springer-Verlag
Publication Date
Dec 12, 2016
Volume
44
Issue
6
Pages
969–978
Identifiers
DOI: 10.1007/s00259-016-3583-2
Source
Springer Nature
Keywords
License
Yellow

Abstract

Purpose18F-fluorodeoxyglucose positron emission tomopraphy/computed tomography (FDGPET/CT) has been proven to be useful for imaging many types of cancer; however, its role is not well defined in hepatocellular carcinoma (HCC). We assessed the prognostic value of metabolic imaging biomarkers as established by baseline pretreatment FDG PET/CT in patients with HCC.MethodsWe retrospectively analyzed the records of patients with HCC who underwent FDG PET/CT before initial treatment from May 2013 through May 2014. Four PET/CT parameters were measured: maximum standardized uptake value (SUVmax), total lesion glycolysis (TLG), metabolic tumor volume (MTV), and tumor-to-normal-liver SUV ratio (TNR). Optimal cut-off values for the PET/CT parameters to stratify patients in terms of overall survival (OS) were determined. Multivariate analysis was performed to determine whether the PET/CT parameters could add to the prognostic value of the Cancer of the Liver Italian Program (CLIP) scoring system and the Barcelona-Clinic Liver Cancer (BCLC) staging system.ResultsThe analysis included 56 patients. Univariate analysis of the association between OS and continuous variables, including the PET/CT parameters SUVmax, TLG, tumor size, total bilirubin level, and alkaline phosphatase level were significant predictors of OS. SUVmax ≥ 11.7, TLG ≥ 1,341, MTV ≥ 230 mL, and TNR ≥ 4.8 were identified as cut-off values. Multivariate analysis revealed that SUVmax ≥ 11.7 and TNR ≥ 4.8 were independent factors predicting a poor prognosis in both the CLIP scoring system and the BCLC staging system, as was TLG in the BCLC staging system.ConclusionPretreatment FDG PET/CT in patients with HCC can add to the prognostic value of standard clinical measures. Incorporation of imaging biomarkers derived from FDG PET/CT into HCC staging systems should be considered.

Report this publication

Statistics

Seen <100 times